Failed the trial but they will move ahead anyways

our goal of providing a safe and effective vaccine against Lyme disease,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head of Vaccine Research and Development, Pfizer.

https://www.pfizer.com/news/press-release/press-release-detail/phase-3-valor-lyme-disease-trial-valneva-and-pfizer

– Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial.

– Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited “strong efficacy” for its decision to move forward.

– Partner Valneva has said the Lyme disease shot could reach annual peak sales of more than $1 billion.

https://www.cnbc.com/2026/03/23/pfizer-lyme-disease-vaccine-trial-fda-approval.html

Its not going to be very popular.

https://www.lymedisease.org/pfizers-new-lyme-vaccine-results/
A fourshot regimen that yields around 70% protection is not exactly a slamdunk solution. And realistically, it may be difficult to get large numbers of people to complete a fourdose series for a vaccine that doesn’t offer nearcomplete protection. Even routine twodose vaccines struggle with completion rates. Asking for double that is a tall order.

h/t Doctor Congo